Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants

University of Alberta

$60,000.00

CD71+ erythroid cells impair tumor immunogenicity and promote tumor progression

EF 2019-20

Résumé
Breast cancer is the most common cancer type and is the leading cause of female mortality worldwide. Unfortunately, the incidence of breast cancer is still increasing in North America. The use of immunotherapy that reinvigorates the immune system against cancer has witnessed an unprecedented revolution in cancer treatment. There is tremendous interest in using immunotherapy to treat breast cancer. However, breast cancer patients do not respond to such treatments. Therefore, there is an urgent need to better understand how the immune system fights breast cancer in particular in the tumor microenvironment. We have found that immature red blood cells are expanded in the blood of breast cancer patients and also in their tumors. These cells suppress the immune system against the cancer and at the same time secrete some proteins that can bind to the breast tumors and expand them. Our project will allow us to better understand how these cells affect tumor progression and how this can be prevented.
Programme
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
422422
Name
Elahi Shokrollah
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
CD71+ erythroid cells impair tumor immunogenicity and promote tumor progression
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Breast Cancer; Cancer Progression; Immunosuppression
Abstract
Breast cancer is the most common cancer type and is the leading cause of female mortality worldwide. Unfortunately, the incidence of breast cancer is still increasing in North America. The use of immunotherapy that reinvigorates the immune system against cancer has witnessed an unprecedented revolution in cancer treatment. There is tremendous interest in using immunotherapy to treat breast cancer. However, breast cancer patients do not respond to such treatments. Therefore, there is an urgent need to better understand how the immune system fights breast cancer in particular in the tumor microenvironment. We have found that immature red blood cells are expanded in the blood of breast cancer patients and also in their tumors. These cells suppress the immune system against the cancer and at the same time secrete some proteins that can bind to the breast tumors and expand them. Our project will allow us to better understand how these cells affect tumor progression and how this can be prevented.
Competitiondate
202002
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Elahi, Shokrollah
Approvedterm
2 ans 0 mois
Cihrcontribution2
Breast Cancer Initiative~ $60,000~ $0~